{"id":450552,"date":"2021-03-04T08:03:32","date_gmt":"2021-03-04T13:03:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450552"},"modified":"2021-03-04T08:03:32","modified_gmt":"2021-03-04T13:03:32","slug":"pharvaris-to-participate-in-biocapital-europe","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/","title":{"rendered":"Pharvaris to Participate in BioCapital Europe"},"content":{"rendered":"
\n

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) — Pharvaris<\/a> (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.<\/p>\n

\n
\n Participation Details:<\/u>
\n <\/strong>
\n
\n Title: <\/strong>\u201cShaping the New Biotech Reality \u2013 Key Lessons from COVID\u201d Panel Presentation
Date\/Time: <\/strong>March 10, 2021, 18:30 CET (12:30 p.m. EST)<\/p>\n

\n Title: <\/strong>Pharvaris Corporate Presentation
Date\/Time: <\/strong>March 11, 2021, 14:50 CET (8:50 a.m. EST)<\/p>\n

The virtual presentation will be available for 30 days on the Pharvaris website at https:\/\/ir.pharvaris.com\/news-events\/events-presentations<\/a>.<\/p>\n

\n About Pharvaris<\/strong>
\n
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https:\/\/pharvaris.com\/<\/a>.<\/p>\n

\n Investor Contact<\/strong>
\n
Chad Rubin, Solebury Trout
crubin@soleburytrout.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Maggie Beller, Russo Partners, LLC
maggie.beller@russopartnersllc.com<\/a>
+1-646-942-5631<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021. Participation Details: Title: \u201cShaping the New Biotech Reality \u2013 Key Lessons from COVID\u201d Panel PresentationDate\/Time: March 10, 2021, 18:30 CET (12:30 p.m. EST) Title: Pharvaris Corporate PresentationDate\/Time: March 11, 2021, 14:50 CET (8:50 a.m. EST) The virtual presentation will be available for 30 days on the Pharvaris website at https:\/\/ir.pharvaris.com\/news-events\/events-presentations. About Pharvaris Pharvaris is a clinical-stage company focused on … <\/p>\n

Continue reading “Pharvaris to Participate in BioCapital Europe”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450552","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPharvaris to Participate in BioCapital Europe - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris to Participate in BioCapital Europe - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021. Participation Details: Title: \u201cShaping the New Biotech Reality \u2013 Key Lessons from COVID\u201d Panel PresentationDate\/Time: March 10, 2021, 18:30 CET (12:30 p.m. EST) Title: Pharvaris Corporate PresentationDate\/Time: March 11, 2021, 14:50 CET (8:50 a.m. EST) The virtual presentation will be available for 30 days on the Pharvaris website at https:\/\/ir.pharvaris.com\/news-events\/events-presentations. About Pharvaris Pharvaris is a clinical-stage company focused on … Continue reading "Pharvaris to Participate in BioCapital Europe"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T13:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharvaris to Participate in BioCapital Europe\",\"datePublished\":\"2021-03-04T13:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/\"},\"wordCount\":210,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/\",\"name\":\"Pharvaris to Participate in BioCapital Europe - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=\",\"datePublished\":\"2021-03-04T13:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-biocapital-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris to Participate in BioCapital Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharvaris to Participate in BioCapital Europe - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/","og_locale":"en_US","og_type":"article","og_title":"Pharvaris to Participate in BioCapital Europe - Market Newsdesk","og_description":"ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021. Participation Details: Title: \u201cShaping the New Biotech Reality \u2013 Key Lessons from COVID\u201d Panel PresentationDate\/Time: March 10, 2021, 18:30 CET (12:30 p.m. EST) Title: Pharvaris Corporate PresentationDate\/Time: March 11, 2021, 14:50 CET (8:50 a.m. EST) The virtual presentation will be available for 30 days on the Pharvaris website at https:\/\/ir.pharvaris.com\/news-events\/events-presentations. About Pharvaris Pharvaris is a clinical-stage company focused on … Continue reading \"Pharvaris to Participate in BioCapital Europe\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T13:03:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharvaris to Participate in BioCapital Europe","datePublished":"2021-03-04T13:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/"},"wordCount":210,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/","name":"Pharvaris to Participate in BioCapital Europe - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=","datePublished":"2021-03-04T13:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ1NCM0MDQ4NTM5IzIyMDU5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-biocapital-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharvaris to Participate in BioCapital Europe"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450552"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450552\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}